BiotechTube
Home/Pipeline/Trastuzumab biosimilar (IBI306)

Trastuzumab biosimilar (IBI306)

Breast cancer

Phase 3Active

Key Facts

Indication
Breast cancer
Phase
Phase 3
Status
Active
Company
Innovent Biologics

About Innovent Biologics

Innovent Biologics is one of China's premier biotechnology companies, established in 2011 and publicly traded on the Hong Kong Stock Exchange. The company specializes in developing innovative biologics for oncology, autoimmune, and metabolic diseases, with a strong focus on monoclonal antibodies and bispecific antibodies. Innovent has successfully commercialized multiple products in China and has strategic partnerships with global pharmaceutical companies including Eli Lilly and Roche.

View full company profile

Therapeutic Areas

OncologyAutoimmuneHematology

Other Breast cancer Drugs

DrugCompanyPhase
Verzenio (abemaciclib)Eli LillyApproved
Pan-mutant-selective PI3Kα inhibitorNovartisAcquisition
TrodelvyRoyalty PharmaCommercial
Ogivri (trastuzumab biosimilar)ViatrisApproved
Trastuzumab BiosimilarDr. Reddy's LaboratoriesApproved
Biosimilar TrastuzumabCiplaCommercial
Ogivri (Trastuzumab)BioconApproved
TamoxifenNatco PharmaApproved
ARV-027ArvinasPhase 1
Prognostic Genomic TestsEurobio ScientificCommercial
SelinexorKaryopharm TherapeuticsClinical Trials
ATNM-400Actinium PharmaceuticalsPreclinical